Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Teshima T, et al. Int J Hematol. 2024 Jul;120(1):106-116. doi: 10.1007/s12185-024-03772-6. Epub 2024 May 25. Int J Hematol. 2024. PMID: 38796666 Free PMC article. Clinical Trial.
Early immune reaction after reduced-intensity cord-blood transplantation for adult patients.
Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T, Kusumi E, Hara S, Matsumura T, Yuji K, Masuoka K, Wake A, Morinaga S, Kanemaru M, Hayashi T, Tanaka Y, Taniguchi S; Tokyo Stem Cell Transplant Consortium. Kishi Y, et al. Among authors: teshima t. Transplantation. 2005 Jul 15;80(1):34-40. doi: 10.1097/01.tp.0000163289.20406.86. Transplantation. 2005. PMID: 16003230
Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, Hatanaka K, Tanimoto M, Harada M, Nakao S, Abe Y, Wake A, Eto T, Takemoto Y, Imamura M, Takahashi S, Ishida Y, Kanda Y, Kasai M, Takaue Y. Teshima T, et al. Br J Haematol. 2005 Aug;130(4):575-87. doi: 10.1111/j.1365-2141.2005.05632.x. Br J Haematol. 2005. PMID: 16098073 Free article.
Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.
Kim SW, Matsuo K, Fukuda T, Hara M, Matsue K, Taniguchi S, Eto T, Tanimoto M, Wake A, Hatanaka K, Nakao S, Ishida Y, Harada M, Utsunomiya A, Imamura M, Kanda Y, Sunami K, Kawano F, Takaue Y, Teshima T. Kim SW, et al. Among authors: teshima t. Int J Hematol. 2008 Oct;88(3):324-330. doi: 10.1007/s12185-008-0163-7. Epub 2008 Sep 17. Int J Hematol. 2008. PMID: 18797985
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; for Fukuoka Blood and Marrow Transplant Group (FBMTG). Takenaka K, et al. Among authors: teshima t. Int J Hematol. 2009 Mar;89(2):231-237. doi: 10.1007/s12185-008-0249-2. Epub 2009 Jan 17. Int J Hematol. 2009. PMID: 19148587 Clinical Trial.
1,121 results